Pulse Biosciences (PLSE) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $264,000 in Q4 2025, up from $86,000 in Q3 2025, driven by sales of both nPulse Capital and Vybrance disposable devices.

Cost of Product Revenue: $260,000 for the quarter, slightly lower than the previous quarter.

GAAP Net Loss: $17.4 million, improved from $19.4 million year-over-year.

Non-GAAP Net Loss: $12.2 million, compared to $10.4 million in the prior year period.

Cash and Cash Equivalents: $80.7 million as of December 31, 2025, down from $118 million at the end of 2024.

Cash Used in Operating Activities: $14.8 million in Q4 2025, an increase from $9.1 million in the prior year.

2Strategic Updates and Business Highlights

Technology Focus: Pulse Biosciences is advancing its nanosecond pulsed field ablation (nsPFA) platform, aiming to disrupt soft tissue ablation markets with precision and speed.

Clinical Development: IDE approvals were secured for both the electrophysiology catheter and cardiac surgical clamp, with pivotal trial enrollment expected to commence shortly.

European Feasibility Studies: Expanded treatment of patients in Europe, generating promising data for both cardiac platforms.

Vybrance Launch: The controlled launch of the Vybrance platform for soft tissue ablation is ongoing, with a focus on select institutions to validate clinical and economic models.

Intellectual Property: Added 67 issued and 77 pending patents in 2025, totaling 250 granted and 180 pending patents.

3Forward Guidance and Outlook

2026 Focus: Plans to complete enrollment in pivotal trials for the nPulse cardiac catheter and cardiac surgical clamp, with CE Mark submissions anticipated by the end of 2026.

Market Development: Continued emphasis on building a solid foundation for Vybrance's market entry, with broader commercialization expected in the next 4 to 8 quarters.

Clinical Evidence Generation: Ongoing efforts to produce clinical data to support future FDA therapeutic clearances.

4Bad News, Challenges, or Points of Concern

Revenue Growth: Although there was sequential revenue growth, total revenue remains nominal, raising concerns about the pace of commercial adoption.

Cash Burn: Increased cash usage in operations, which may necessitate additional funding or partnerships to sustain operations and clinical programs.

Regulatory Challenges: The timeline for achieving FDA therapeutic clearances is extended, with expectations set for 2027, which may impact market entry and revenue generation.

Integration Issues: Concerns were raised regarding the integration of the nPulse system with mapping technologies, which could affect clinical adoption.

5Notable Q&A Insights

Vybrance Expansion: Management emphasized the importance of building a strong foundation before scaling the Vybrance launch, focusing on data-driven outcomes and reimbursement processes.

nPulse Reception: Positive feedback from the AF Symposium regarding nPulse's clinical outcomes, with expectations for accelerated enrollment in pivotal studies due to heightened physician interest.

Next-Gen nPulse: Development of a next-generation nPulse system is underway, aiming for improved integration and procedural benefits, though timelines remain unspecified.

Partnership Strategy: The company is exploring partnerships to enhance commercialization and funding opportunities, particularly as it awaits regulatory approvals. Overall, while Pulse Biosciences is making significant strides in clinical development and technology validation, it faces challenges related to revenue generation, cash burn, and regulatory timelines that could impact its growth trajectory in the near term.